6 results
Primary objectiveTo determine the feasibility of plerixafor 320 *g/kg subcutaneously to harvest a sufficient number of CD34+ peripheral blood stem cells/kg recipient body weight. Feasibilty is defined as a minimum of 2.0x10^6/kg CD34+ cells in one…
To assess whether the use of RFIB instead of LCNB increases the probability of a definitive preoperative histological diagnosis in women with suspicious mammographic breast lesions. assess the *RFIB success rate*, defined as the proportion of…
Primary Objective: * To confirm the safety profile of plerixafor to mobilise stem cells when used in patients with lymphoma or MM who are eligible to undergo treatment with an autologous haematopoietic stem cell transplantSecondary Objectives:* To…
This clinical trial will test the safety and performance of the Spinal Modulation Neurostimulator System in the treatment of chronic pain.Outcomes:Primary Outcomes: 1) Safety as determined by adverse event reporting2) Device performance as…
In this study, plerixafor, the study drug, will be given in addition to GCSF to see if it works the same way in children as in adults.
To demonstrate that Plerixafor is able to reduce the need for invasive mechanical ventilation or death in severe COVID-19 patients admitted in Intensive Care Unit (ICU)